Opendata, web and dolomites

GenomtecTumor SIGNED

MicroRNA-based tool for non-invasive early-stage cancer diagnosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "GenomtecTumor" data sheet

The following table provides information about the project.

Coordinator
GENOMTEC SPOLKA AKCYJNA 

Organization address
address: KRAKOWSKA 141-155
city: WROCLAW
postcode: 50 428
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Poland [PL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOMTEC SPOLKA AKCYJNA PL (WROCLAW) coordinator 50˙000.00

Map

 Project objective

The goal of this project is to develop a portable and easy to use device for early cancer diagnosis to maximise patient outcomes. Cancer is a major public health problem and a leading cause of morbidity and death with over 14.1 million cases reported worldwide every year. Early cancer diagnosis is critical to its successful treatment, yet today’s technologies are limited in their accuracy, and are laborious and time consuming processes.

Genomtec aims to address this challenge with its novel diagnostic system based on unique, patent pending amplification technology – Streamlined Nucleic Acid Amplification Technology (SNAATTM). Genomtec’s programme is built on many years of R&D activity and collaborative projects with academic and medical institutions in Poland. Using this robust molecular biology method for real-time amplification of nucleic acids, Genomtec’s cancer diagnostic test can be performed in 20 minutes at the point-of-care.

Genomtec offers the possibility to accurately diagnose cancer early and reduce its financial burden on the economy by enabling more effective treatment and improved patient outcomes, including increased patient survival, increased post-treatment quality of life, and reduced patient distress during the diagnostic phase. Genomtec’s diagnostic device is unique and there are no competitors using the same molecular approach to diagnose cancer based on detection of tumour specific microRNA.

The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for sales expansion. Genomtec plans to apply for the SME Phase 2 grant to take its product through device finalisation, clinical studies, and establishment of the distribution network. Genomtec has an established business development contact network and has been awarded numerous prizes for its innovativeness and potential for growth, e.g. The best non-US startup at Boston HUBWeek in October 2018.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GENOMTECTUMOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GENOMTECTUMOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

ChromicGlass (2019)

FAST-RESPONSIVE and LONG-LASTING TRANSPARENT PHOTOCHROMIC FILMS

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More